Annual Meeting of Japanese Association of Breast Cancer Screening, Okinawa. In a prospective study EpiSwitch™ technology identifies a patient who develops breast cancer two years ahead of confirmation.

Okinawa. November 10, 2012. At the Annual Meeting of the Japanese Association of Breast Cancer Screening, Dr Nomizu presented the results of the EpiSwitchTM analysis, conducted by OBD in collaboration with Otsuka Pharmaceutical Co. Limited. A prospective study has been conducted on the patient, who was diagnosed as healthy by both mammography and ultrasonic examination, but was identified with deregulation, symptomatic of breast cancer, by the EpiSwitchTM technology. Observations carried out over a two year period confirmed that the patient had developed stage 1 breast cancer, with a tumour size of 15 mm.